1. Home
  2. CINGW vs UDR Comparison

CINGW vs UDR Comparison

Compare CINGW & UDR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CINGW
  • UDR
  • Stock Information
  • Founded
  • CINGW N/A
  • UDR 1972
  • Country
  • CINGW United States
  • UDR United States
  • Employees
  • CINGW 13
  • UDR N/A
  • Industry
  • CINGW Biotechnology: Pharmaceutical Preparations
  • UDR Real Estate Investment Trusts
  • Sector
  • CINGW Health Care
  • UDR Real Estate
  • Exchange
  • CINGW Nasdaq
  • UDR Nasdaq
  • Market Cap
  • CINGW N/A
  • UDR N/A
  • IPO Year
  • CINGW 2021
  • UDR N/A
  • Fundamental
  • Price
  • CINGW $0.09
  • UDR $43.29
  • Analyst Decision
  • CINGW
  • UDR Hold
  • Analyst Count
  • CINGW 0
  • UDR 20
  • Target Price
  • CINGW N/A
  • UDR $43.00
  • AVG Volume (30 Days)
  • CINGW N/A
  • UDR 2.1M
  • Earning Date
  • CINGW N/A
  • UDR 10-24-2024
  • Dividend Yield
  • CINGW N/A
  • UDR 3.92%
  • EPS Growth
  • CINGW N/A
  • UDR N/A
  • EPS
  • CINGW N/A
  • UDR 0.40
  • Revenue
  • CINGW N/A
  • UDR $1,675,078,000.00
  • Revenue This Year
  • CINGW N/A
  • UDR N/A
  • Revenue Next Year
  • CINGW N/A
  • UDR $0.71
  • P/E Ratio
  • CINGW N/A
  • UDR $108.24
  • Revenue Growth
  • CINGW N/A
  • UDR 0.76
  • 52 Week Low
  • CINGW N/A
  • UDR $30.95
  • 52 Week High
  • CINGW N/A
  • UDR $47.55
  • Technical
  • Relative Strength Index (RSI)
  • CINGW N/A
  • UDR 42.55
  • Support Level
  • CINGW N/A
  • UDR $44.40
  • Resistance Level
  • CINGW N/A
  • UDR $44.58
  • Average True Range (ATR)
  • CINGW 0.00
  • UDR 0.69
  • MACD
  • CINGW 0.00
  • UDR -0.31
  • Stochastic Oscillator
  • CINGW 0.00
  • UDR 14.98

About CINGW Cingulate Inc.

Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.

Share on Social Networks: